PGEN — Recent News Coverage
All news mentioning PGEN in ESEN's AI-graded feed
News stories with PGEN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on PGEN. See /coverage/PGEN for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-08
NEUTRAL
NEUTRAL
CORR0.35
Precigen Stock Has To Grow Into Its Valuation (NASDAQ:PGEN)
$PGEN
◈ ESEN AI
PGEN experienced upward momentum following FDA approval of PAPZIMEOS, a meaningful validation of the company's clinical development efforts in its therapeutic area. However, the article frames this approval as a double-…
SEEKINGALPHA.COM
·
2026-08-06
NEUTRAL
BULLISH
CORR0.32
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement (PGEN)
$PGEN
◈ ESEN AI
Precigen (PGEN) received a Strong Buy upgrade following FDA approval for its PAPZIMEOS therapeutic, which addresses recurrent respiratory papillomatosis (RRP). The approval represents a significant clinical validation e…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
BULLISH
CORR0.42
Precigen anticipates PAPZIMEOS gross margin stabilizing in the high 80% to low 90% range as it targets cash flow breakeven by end of 2026 (NASDAQ:PGEN)
$PGEN
◈ ESEN AI
Precigen (PGEN) reported exceptional Q2 2026 performance driven by PAPZIMEOS revenue acceleration, which surged 145% year-over-year to $53.1M. This represents a material inflection point for the company's flagship oncol…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.45
Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript
$PGEN
◈ ESEN AI
Precigen (PGEN) released Q2 2026 earnings results via an earnings call transcript, which represents standard quarterly disclosure activity. Earnings call transcripts are routine communication events that provide managem…
SEEKINGALPHA.COM
·
2026-06-26
NEUTRAL
BULLISH
CORR0.42
Precigen: Entering The Oncology "Sweet Spot" (NASDAQ:PGEN)
$PGEN
◈ ESEN AI
Precigen (PGEN) has received a STRONG BUY rating based on commercial momentum in its oncology portfolio, specifically citing PAPZIMEOS as a key revenue driver. This analyst upgrade reflects confidence in the company's a…
BENZINGA.COM
·
2026-06-15
NEUTRAL
BULLISH
CORR0.42
Precigen Gains Advantage As PAPZIMEOS Granted Orphan Drug Exclusivity By FDA; Long-Term Data From Clinica
$PGEN
◈ ESEN AI
Precigen (PGEN) has secured orphan drug exclusivity designation from the FDA for PAPZIMEOS, a narrowly-focused therapeutic addressing recurrent respiratory papillomatosis (RRP). This regulatory milestone provides the co…
RTTNEWS.COM
·
2026-06-12
NEUTRAL
BULLISH
CORR0.42
Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch...
$ADIL
$PGEN
$PCSA
◈ ESEN AI
ADIL announced the acquisition of Azora Therapeutics, a strategic move designed to expand its clinical pipeline and enhance its competitive positioning within the specialty pharmaceutical space. This M&A activity signal…
EXPLORE OTHER FILTERS